NEWS & ARTICLES
OM1 Lupus Registry Reaches More Than 25,000 Patients Prospectively Followed With Deep Clinical And Lab Data
OCT 23, 2018
OM1 LUPUS REGISTRY REACHES MORE THAN 25,000 PATIENTS PROSPECTIVELY FOLLOWED WITH DEEP CLINICAL AND LAB DATA Ready for collaborations, the registry enables faster, more cost-effective access to research-grade lupus data for better understanding, comparing, and predicting treatment outcomes BOSTON, October 17, 2018 — OM1, a leading health outcomes, registries and technology company creating solutions to[…]
Health Outcomes & Technology Company OM1 Closes $21 Million Series B Financing and Expands Product Offerings
MAY 22, 2018
HEALTH OUTCOMES & TECHNOLOGY COMPANY OM1 CLOSES $21 MILLION SERIES B FINANCING AND EXPANDS PRODUCT OFFERINGS Polaris Partners led the investment and Dave Barrett joins the Board of Directors as the team expands its intelligent data cloud and curated registries for measuring, comparing and predicting health outcomes BOSTON, May 22, 2018 — OM1, a leading[…]
WHITE PAPERS
From Big Data to Measurable Outcomes: OBC
JUL 6, 2017
A heightened focus on value is driving efforts across health care to improve outcomes and reduce costs. For pharmaceutical companies, this focus translates into a shift away from traditional payment models to more outcomes-based, risk sharing agreements. In many ways, these agreements present the opportunity to better align interests across health care’s stakeholders. However, they[…]
Improving Performance under Bundled Care
NOV 5, 2016
The field of medicine is changing rapidly due to two major disruptions – the application of artificial intelligence, such as machine and deep learning and the shift from fee-for-service to value-based payment models. These innovations, which are occurring simultaneously, are fundamentally altering how data are used and how care is provided. To survive in this[…]
WEBINARS
Aug 30 – Next Generation Registries: Big Data, Advanced Analytics, More Dynamic Evidence
AUG 14, 2018
August 30, 2018 – 2:00 – 3:00 pm ET Registries continue to be a critical part of the real-world evidence equation, but over time they have become too trialized, too burdensome, and too separated from real clinical practice. Emerging methodologies, data digitization, and cognitive technologies have set the path for drastic changes needed to address[…]
Using Big Data Like Biomarkers to Advance Clinical Development & Commercialization
MAR 5, 2018
March 28, 2018 – 2 PM ET What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice? What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to[…]